JP2009525758A5 - - Google Patents

Download PDF

Info

Publication number
JP2009525758A5
JP2009525758A5 JP2008554427A JP2008554427A JP2009525758A5 JP 2009525758 A5 JP2009525758 A5 JP 2009525758A5 JP 2008554427 A JP2008554427 A JP 2008554427A JP 2008554427 A JP2008554427 A JP 2008554427A JP 2009525758 A5 JP2009525758 A5 JP 2009525758A5
Authority
JP
Japan
Prior art keywords
antibody
par
binding protein
antigen binding
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008554427A
Other languages
English (en)
Japanese (ja)
Other versions
JP5255453B2 (ja
JP2009525758A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/003796 external-priority patent/WO2007092640A2/en
Publication of JP2009525758A publication Critical patent/JP2009525758A/ja
Publication of JP2009525758A5 publication Critical patent/JP2009525758A5/ja
Application granted granted Critical
Publication of JP5255453B2 publication Critical patent/JP5255453B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008554427A 2006-02-10 2007-02-09 Par−2に結合する抗体 Active JP5255453B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77245606P 2006-02-10 2006-02-10
US60/772,456 2006-02-10
PCT/US2007/003796 WO2007092640A2 (en) 2006-02-10 2007-02-09 Antibodies that bind par-2

Publications (3)

Publication Number Publication Date
JP2009525758A JP2009525758A (ja) 2009-07-16
JP2009525758A5 true JP2009525758A5 (https=) 2010-04-02
JP5255453B2 JP5255453B2 (ja) 2013-08-07

Family

ID=38345850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008554427A Active JP5255453B2 (ja) 2006-02-10 2007-02-09 Par−2に結合する抗体

Country Status (8)

Country Link
US (3) US7888482B2 (https=)
EP (1) EP1981913B1 (https=)
JP (1) JP5255453B2 (https=)
AU (1) AU2007212195B2 (https=)
CA (1) CA2638849C (https=)
ES (1) ES2476892T3 (https=)
MX (1) MX2008009886A (https=)
WO (1) WO2007092640A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
EP2215474A4 (en) * 2007-07-16 2012-07-18 Avaxia Biologics Inc ANTIBODY THERAPY FOR MODULATING THE FUNCTION OF DARM RECEPTORS
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
EP2313110A1 (en) * 2008-08-05 2011-04-27 Boehringer Ingelheim International GmbH Effectors of par-2 activation and their use in the modulation of inflammation
WO2010132954A1 (en) * 2009-05-21 2010-11-25 Oral Health Australia Pty Ltd Method of treating periodontal disease by administering antagonists of par-2
JO3246B1 (ar) 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
MY162557A (en) 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection
WO2012077105A2 (en) * 2010-12-07 2012-06-14 Bio-Marcare Technologies Ltd. Biomarkers for detecting a cancerous state in a subject
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
HK1223096A1 (zh) 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
KR20220098056A (ko) * 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
SMT202500106T1 (it) 2020-08-18 2025-05-12 Cephalon Llc Anticorpi anti-par-2 e loro metodi d'uso
CN112229996A (zh) * 2020-08-25 2021-01-15 深圳市第二人民医院(深圳市转化医学研究院) 蛋白酶激活受体2作为宫颈癌转移检测标志物的应用
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
US20250076309A1 (en) 2021-10-05 2025-03-06 Amgen Inc. Fc-gamma receptor ii binding and glycan content
GB202204159D0 (en) * 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716789A (en) 1993-07-26 1998-02-10 Cor Therapeutics, Inc. Method to determine ligands, agonist and antagonist of C140 receptor
US5629174A (en) 1993-07-26 1997-05-13 Cor Therapeutics, Inc. Recombinant C140 receptor
WO2001000656A2 (en) * 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
AU2001231030A1 (en) 2000-01-20 2001-07-31 Amgen Inc Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
WO2004080373A2 (en) 2003-03-11 2004-09-23 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
EP2313110A1 (en) 2008-08-05 2011-04-27 Boehringer Ingelheim International GmbH Effectors of par-2 activation and their use in the modulation of inflammation

Similar Documents

Publication Publication Date Title
JP2009525758A5 (https=)
JP2009142293A5 (https=)
CN109789201B (zh) 抗人vista抗体及其用途
JP2015535820A5 (https=)
RU2008132968A (ru) Антитела к рецептору тимусного стромального лимфопоэтина
Chu et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody
JP2022163013A5 (https=)
JP2008530132A5 (https=)
JP2010538608A5 (https=)
JP2006507839A5 (https=)
JP2009297037A5 (https=)
RU2012128856A (ru) Мыши, которые производят антитела, имеющие только тяжелую цепь
RU2015149617A (ru) Моноклональные антитела против клаудина-18 для лечения рака
JP2018046872A5 (https=)
WO2004035607A8 (en) Human monoclonal antibodies against cd20
CA2456648A1 (en) Human antibodies specific for interleukin 15 (il-15)
JP2010529042A5 (https=)
JP2010246565A5 (https=)
HRP20141226T1 (hr) Anti-ilt7 protutijelo
JP2013198490A5 (https=)
JP2009005695A5 (https=)
JP2017052784A5 (https=)
JP2013506428A5 (https=)
JP2013517330A5 (https=)
JP2012523848A5 (https=)